Comparación de Basiliximab vs. Daclizumab en dosis reducida (2 mg/kg) administrado en dosis única o en dos dosis en receptores de trasplante renal

No abstract is available for this paper.

• Publication year

  2008

• Venue

  Revista De Investigacion Clinica

• Publication date

  2008-03-01

• Fields of study

  Not labeled

• Identifiers

  No identifiers available.

• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Anti-CD25 treatment and FOXP3-positive regulatory T cells in heart transplantation.

  2007cited by this paper
• Experience with single-dose daclizumab in the prevention of acute rejection in heart transplantation.

  2005cited by this paper
• Limited-dose Daclizumab versus Basiliximab: a comparison of cost and efficacy in preventing acute rejection.

  2005cited by this paper
• Single-dose daclizumab induction therapy in patients with liver transplantation.

  2003cited by this paper
• Interleukin-2 receptor monoclonal antibodies in renal transplantation: meta-analysis of randomised trials

  2003cited by this paper
• Pharmacokinetic and Pharmacodynamic Studies of One or Two Doses of Daclizumab in Renal Transplantation

  2003cited by this paper
• Long‐term Safety, Tolerability and Efficacy of Daclizumab (Zenapax®) in a Two‐dose Regimen in Liver Transplant Recipients

  2002cited by this paper
• Reduction of acute allograft rejection by daclizumab

  1999cited by this paper
• Daclizumab: novel biologic immunoprophylaxis for prevention of acute rejection in renal transplantation.

  1999cited by this paper
• Randomised trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients

  1997cited by this paper
• A phase I trial of humanized anti-interleukin 2 receptor antibody in renal transplantation.

  1997cited by this paper

• Advances in Immunosuppressive Therapy

  2015cites this paper
• Risk of serious opportunistic infections after solid organ transplantation: interleukin-2 receptor antagonists versus polyclonal antibodies. A meta-analysis

  2014cites this paper
• Outcome and Cost Analysis of Induction Immunosuppression With IL2Mab or ATG in DCD Kidney Transplants

  2014cites this paper
• Combination of a low dose of daclizumab and standard regimen for prevention of rejection in men and women receiving a kidney transplant.

  2013cites this paper
• THE EFFECT OF ADDING LOW DOSE DACLIZUMAB TO RENAL TRANSPLANTATION STANDARD PROTOCOL ON REDUCTION THE RISK OF KIDNEY REJECTION IN RENAL ALLOGRAFT RECIPIENTS

  2012cites this paper
• Prophylactic effects of interleukin-2 receptor antagonists against graft-versus-host disease following unrelated donor peripheral blood stem cell transplantation.

  2012cites this paper
• Postoperative Care of the Transplanted Patient

  2011cites this paper
• Immunosuppressive Therapy in Kidney and Pancreas Transplantation

  2011cites this paper
• High rejection rates with low dose immunosuppression in old for old kidney transplantation

  2011cites this paper
• The outcome of induction therapy with monoclonal antibodies in kidney transplantation among Iranian patients: a prospective study.

  2009cites this paper